Cyclerion Therapeutics, Inc. (CYCN) Earnings History
Net Loss9 years of earnings data (2017–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Cyclerion Therapeutics, Inc. (CYCN) Earnings Overview
As of June 22, 2026, Cyclerion Therapeutics, Inc. (CYCN) reported trailing twelve-month net income of -$5M, reflecting +9.9% year-over-year growth. The company earned $-1.25 per diluted share over the past four quarters, with a net profit margin of -170.1%.
Looking at the long-term picture, CYCN's historical earnings data spans multiple years. The company achieved its highest annual net income of -$3M in fiscal 2024.
Cyclerion Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ADMA ($165M net income, 28.8% margin), IMVT (-$506M net income), KALA (-$20M net income), CYCN has room to improve margins relative to the peer group. Compare CYCN vs ADMA →
CYCN Earnings vs Peers
Earnings metrics vs comparable public companies
CYCN Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$4M | -15.4% | -$5M | $-1.09 | -170.1% | -239.8% |
| 2024 | -$3M | +41.9% | -$4M | $-1.21 | -152.8% | -181.4% |
| 2023 | -$5M | +88.1% | -$13M | $-8.99 | - | - |
| 2022 | -$44M | +14.7% | -$19M | $-20.15 | -14841.1% | -6242.4% |
| 2021 | -$52M | +33.6% | -$55M | $-26.40 | -1555.6% | -1662.5% |
| 2020 | -$78M | +36.8% | -$81M | $-47.80 | -3388.6% | -3539.4% |
| 2019 | -$123M | -6.7% | -$125M | $-88.37 | -2729.3% | -2774.3% |
| 2018 | -$115M | -22.7% | -$115M | $-84.42 | - | - |
| 2017 | -$94M | - | -$94M | $-68.80 | - | - |
Download Data
Export CYCN earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CYCN — Frequently Asked Questions
Quick answers to the most common questions about buying CYCN stock.
What is CYCN earnings per share (EPS)?
CYCN trailing twelve-month (TTM) diluted EPS is $-1.25, reflecting +9.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2017 to 2025 is available in the table on this page.
What is Cyclerion Therapeutics, Inc.'s net income?
Cyclerion Therapeutics, Inc. (CYCN) trailing twelve-month net income is $-5M as of 2025. Earnings grew +9.9% year-over-year.
Is CYCN profitable?
CYCN is not currently profitable on a TTM basis, reporting a net loss of $-5M. Net margin is -170.1%. Investors should monitor for a return to profitability.
What is CYCN's earnings growth rate?
CYCN compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2017 to 2025.
What are CYCN's profit margins?
Cyclerion Therapeutics, Inc. net profit margin is -170.1%, operating margin is -239.8%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -39.3%.
Is CYCN growing earnings?
CYCN is growing earnings steadily. YoY EPS growth of +9.9% is consistent with the 5-year CAGR of N/A. TTM net income is $-5M.
What was CYCN's best earnings year?
Cyclerion Therapeutics, Inc.'s highest annual net income on record is $-3M, achieved in fiscal year 2024. Earnings history on this page spans 2017 to 2025 and includes all annual and quarterly figures.
What were CYCN's earnings last quarter?
CYCN's most recent reported quarter was Q1 2026. Net income was $-3M with diluted EPS of $-0.76. For a full breakdown of all quarters, see the quarterly earnings table on this page.